Abstract
The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Current Molecular Medicine
Title: The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Volume: 8 Issue: 2
Author(s): Kerstin Reimers, Claudia Y.U. Choi, Vesna Bucan and Peter M. Vogt
Affiliation:
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Abstract: The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Export Options
About this article
Cite this article as:
Reimers Kerstin, Choi Y.U. Claudia, Bucan Vesna and Vogt M. Peter, The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis, Current Molecular Medicine 2008; 8 (2) . https://dx.doi.org/10.2174/156652408783769562
DOI https://dx.doi.org/10.2174/156652408783769562 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Head and Neck Cancer Treatments through Chemotherapy to Magnetic
Systems: Perspectives and Challenges
Current Radiopharmaceuticals ABC Transporters: Regulation and Association with Multidrug Resistance in Hepatocellular Carcinoma and Colorectal Carcinoma
Current Medicinal Chemistry Inorganic Nanoparticles for Enhanced Photodynamic Cancer Therapy
Current Drug Discovery Technologies Non-diabetic Glucose levels and Cancer Mortality: A Literature Review
Current Diabetes Reviews Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Letters in Drug Design & Discovery Androgen Receptor Cofactors in Prostate Cancer: Potential Therapeutic Targets of Castration-Resistant Prostate Cancer
Current Cancer Drug Targets Electrochemical Biosensors as a Screening Tool of In Vitro DNA-Drug Interaction
Current Pharmaceutical Analysis Phyto-Phospholipid Complexation as a Novel Drug Delivery System for Management of Cancer with Better Bioavailability: Current Perspectives and Future Prospects
Anti-Cancer Agents in Medicinal Chemistry Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry TRPM8 Biology and Medicinal Chemistry
Current Topics in Medicinal Chemistry The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets In Vivo Inhibition of the Estrogen Sulfatase Enzyme and Growth of DMBA-Induced Mammary Tumors by Melatonin
Current Cancer Drug Targets Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Exosomes Harnessed as Nanocarriers for Cancer Therapy - Current Status and Potential for Future Clinical Applications
Current Molecular Medicine Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Current Cancer Drug Targets A Common Biological Mechanism in Cancer and Alzheimers Disease?
Current Alzheimer Research PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Current Medicinal Chemistry Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued)